What are the clinical benefits of tocilizumab for COVID-19 patients? Evidence from available case-control studies

Detalles Bibliográficos
Autores principales: Ghazvini, Kiarash, Karbalaei, Mohsen, Keikha, Masoud
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Masson SAS. 2021
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7657604/
http://dx.doi.org/10.1016/j.phclin.2020.11.003
_version_ 1783608539358429184
author Ghazvini, Kiarash
Karbalaei, Mohsen
Keikha, Masoud
author_facet Ghazvini, Kiarash
Karbalaei, Mohsen
Keikha, Masoud
author_sort Ghazvini, Kiarash
collection PubMed
description
format Online
Article
Text
id pubmed-7657604
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Elsevier Masson SAS.
record_format MEDLINE/PubMed
spelling pubmed-76576042020-11-12 What are the clinical benefits of tocilizumab for COVID-19 patients? Evidence from available case-control studies Ghazvini, Kiarash Karbalaei, Mohsen Keikha, Masoud Le Pharmacien Hospitalier & Clinicien Letter to the Editor Elsevier Masson SAS. 2021-06 2020-11-11 /pmc/articles/PMC7657604/ http://dx.doi.org/10.1016/j.phclin.2020.11.003 Text en © 2020 Elsevier Masson SAS. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Letter to the Editor
Ghazvini, Kiarash
Karbalaei, Mohsen
Keikha, Masoud
What are the clinical benefits of tocilizumab for COVID-19 patients? Evidence from available case-control studies
title What are the clinical benefits of tocilizumab for COVID-19 patients? Evidence from available case-control studies
title_full What are the clinical benefits of tocilizumab for COVID-19 patients? Evidence from available case-control studies
title_fullStr What are the clinical benefits of tocilizumab for COVID-19 patients? Evidence from available case-control studies
title_full_unstemmed What are the clinical benefits of tocilizumab for COVID-19 patients? Evidence from available case-control studies
title_short What are the clinical benefits of tocilizumab for COVID-19 patients? Evidence from available case-control studies
title_sort what are the clinical benefits of tocilizumab for covid-19 patients? evidence from available case-control studies
topic Letter to the Editor
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7657604/
http://dx.doi.org/10.1016/j.phclin.2020.11.003
work_keys_str_mv AT ghazvinikiarash whataretheclinicalbenefitsoftocilizumabforcovid19patientsevidencefromavailablecasecontrolstudies
AT karbalaeimohsen whataretheclinicalbenefitsoftocilizumabforcovid19patientsevidencefromavailablecasecontrolstudies
AT keikhamasoud whataretheclinicalbenefitsoftocilizumabforcovid19patientsevidencefromavailablecasecontrolstudies

Ejemplares similares